MIRUM PHARMACEUTICALS INC (MIRM)

US6047491013 - Common Stock

25.9  -0.49 (-1.86%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to MIRM. MIRM was compared to 587 industry peers in the Biotechnology industry. MIRM has a bad profitability rating. Also its financial health evaluation is rather negative. MIRM is quite expensive at the moment. It does show a decent growth rate.



Quickly go to:

2

1. Profitability

1.1 Basic Checks

MIRM had negative earnings in the past year.
In the past year MIRM has reported a negative cash flow from operations.
In the past 5 years MIRM always reported negative net income.
MIRM had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

MIRM's Return On Assets of -25.27% is fine compared to the rest of the industry. MIRM outperforms 76.92% of its industry peers.
MIRM has a Return On Equity (-65.72%) which is in line with its industry peers.
Industry RankSector Rank
ROA -25.27%
ROE -65.72%
ROIC N/A
ROA(3y)-30.74%
ROA(5y)-34.18%
ROE(3y)-77.04%
ROE(5y)-66.29%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

With an excellent Gross Margin value of 74.76%, MIRM belongs to the best of the industry, outperforming 85.47% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for MIRM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 74.76%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

3

2. Health

2.1 Basic Checks

MIRM does not have a ROIC to compare to the WACC, probably because it is not profitable.
MIRM has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, MIRM has more shares outstanding
The debt/assets ratio for MIRM is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of 0.96, we must say that MIRM is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of MIRM (0.96) is better than 63.93% of its industry peers.
A Debt/Equity ratio of 1.23 is on the high side and indicates that MIRM has dependencies on debt financing.
The Debt to Equity ratio of MIRM (1.23) is worse than 79.83% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.23
Debt/FCF N/A
Altman-Z 0.96
ROIC/WACCN/A
WACC8.51%

2.3 Liquidity

MIRM has a Current Ratio of 4.45. This indicates that MIRM is financially healthy and has no problem in meeting its short term obligations.
MIRM has a Current ratio (4.45) which is in line with its industry peers.
A Quick Ratio of 4.19 indicates that MIRM has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 4.19, MIRM is in line with its industry, outperforming 48.21% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.45
Quick Ratio 4.19

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 1.17% over the past year.
Looking at the last year, MIRM shows a very strong growth in Revenue. The Revenue has grown by 141.87%.
EPS 1Y (TTM)1.17%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q33.13%
Revenue 1Y (TTM)141.87%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2Q149.21%

3.2 Future

Based on estimates for the next years, MIRM will show a very strong growth in Earnings Per Share. The EPS will grow by 27.63% on average per year.
The Revenue is expected to grow by 35.33% on average over the next years. This is a very strong growth
EPS Next Y68.44%
EPS Next 2Y48.11%
EPS Next 3Y39.19%
EPS Next 5Y27.63%
Revenue Next Year71.63%
Revenue Next 2Y51.26%
Revenue Next 3Y42.34%
Revenue Next 5Y35.33%

3.3 Evolution

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MIRM. In the last year negative earnings were reported.
Also next year MIRM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

MIRM's earnings are expected to grow with 39.19% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y48.11%
EPS Next 3Y39.19%

More info and screens

0

5. Dividend

5.1 Amount

MIRM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MIRUM PHARMACEUTICALS INC

NASDAQ:MIRM (5/7/2024, 9:41:17 AM)

25.9

-0.49 (-1.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.22B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.27%
ROE -65.72%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 74.76%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 1.23
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 4.45
Quick Ratio 4.19
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)1.17%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y68.44%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)141.87%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y